MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects of serotonergic hallucinogen mescaline have been approved by the local Swiss ethics committee. The trial is set to start next month at the University Hospital Basel Liechti Lab, in Basel, Switzerland. Mescaline is an archetypical psychedelic that has a long … Continue reading MindMed’s Mescaline Study Approved For Clinical Trial